Structure-Based Drug Discovery is a collection of methods which exploit the ability to determine and analyse the three-dimensional structure of biological molecules. These methods have been adopted and enhanced to improve the speed and quality of drug discovery. After an introductory overview of the principles and applications of structure-based methods in drug discovery, the essential features of the various methods are explored. Chapters on X-ray crystallography, NMR spectroscopy, computational chemistry and molecular modelling describe how these particular techniques have been enhanced to support rational drug discovery, with discussions on developments such as high-throughput structure determination, probing protein-ligand interactions by NMR spectroscopy, virtual screening, and fragment-based drug discovery. The concluding chapters complement the overview of methods by presenting case histories which demonstrate the major impact that structure-based methods have had on the drug discovery process. Written by international experts from industry and academia, this comprehensive introduction to the methods and practice of structure-based drug discovery not only illustrates leading-edge science but also provides useful scientific background for the non-expert reader. The book presents a balanced appraisal of what structure-based methods can and cannot contribute to drug discovery. It will appeal to industrial and academic researchers in pharmaceutical sciences, medicinal chemistry and chemical biology, as well as providing an insight into the field for recent graduates in the biomolecular sciences. TOC:3D Structure and the Drug Discovery Process.- Structure Determination: Crystallography for Structure-based Drug Design.- Molecular Modelling.- Applications of NMR in Structure-based Drug Design.- Fragment Screening: An Introduction.- Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally-Available Antithrombotic Candidate LY517717.- Anti-Influenza Drugs from Sialidase Inhibitors.- Isoform Specificity: The Design of Estrogen Receptor-Selective Compounds.
Rod Hubbard has been developing and applying methods to study aspects of protein structure for the past twenty five years. In the 1980s, he developed the molecular modelling and graphics programs QUANTA which is still in use today. From the mid 1980s he helped to build up the Structural Biology Laboratory at York of which he was Director from 1992-2001. During the 1990s, his personal research interests focused on protein-ligand interactions and the structures of therapeutically important proteins such as humanized antibodies, kinases, proteases and nuclear receptors. Since 2001, he has spent part of his time at Vernalis (formerly RiboTargets), establishing structure-based drug discovery. As well as the positions at York and Vernalis, he is also a consultant on structure-based discovery methods to various software, biotechnology and pharmaceutical companies.
Show moreStructure-Based Drug Discovery is a collection of methods which exploit the ability to determine and analyse the three-dimensional structure of biological molecules. These methods have been adopted and enhanced to improve the speed and quality of drug discovery. After an introductory overview of the principles and applications of structure-based methods in drug discovery, the essential features of the various methods are explored. Chapters on X-ray crystallography, NMR spectroscopy, computational chemistry and molecular modelling describe how these particular techniques have been enhanced to support rational drug discovery, with discussions on developments such as high-throughput structure determination, probing protein-ligand interactions by NMR spectroscopy, virtual screening, and fragment-based drug discovery. The concluding chapters complement the overview of methods by presenting case histories which demonstrate the major impact that structure-based methods have had on the drug discovery process. Written by international experts from industry and academia, this comprehensive introduction to the methods and practice of structure-based drug discovery not only illustrates leading-edge science but also provides useful scientific background for the non-expert reader. The book presents a balanced appraisal of what structure-based methods can and cannot contribute to drug discovery. It will appeal to industrial and academic researchers in pharmaceutical sciences, medicinal chemistry and chemical biology, as well as providing an insight into the field for recent graduates in the biomolecular sciences. TOC:3D Structure and the Drug Discovery Process.- Structure Determination: Crystallography for Structure-based Drug Design.- Molecular Modelling.- Applications of NMR in Structure-based Drug Design.- Fragment Screening: An Introduction.- Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally-Available Antithrombotic Candidate LY517717.- Anti-Influenza Drugs from Sialidase Inhibitors.- Isoform Specificity: The Design of Estrogen Receptor-Selective Compounds.
Rod Hubbard has been developing and applying methods to study aspects of protein structure for the past twenty five years. In the 1980s, he developed the molecular modelling and graphics programs QUANTA which is still in use today. From the mid 1980s he helped to build up the Structural Biology Laboratory at York of which he was Director from 1992-2001. During the 1990s, his personal research interests focused on protein-ligand interactions and the structures of therapeutically important proteins such as humanized antibodies, kinases, proteases and nuclear receptors. Since 2001, he has spent part of his time at Vernalis (formerly RiboTargets), establishing structure-based drug discovery. As well as the positions at York and Vernalis, he is also a consultant on structure-based discovery methods to various software, biotechnology and pharmaceutical companies.
Show moreChapter 1: 3D Structure and the Drug Discovery Process;
1: Introduction;
2: The Drug Discovery Process;
3: What is Structure-based Drug Discovery?;
4: The Evolution of the Ideas of Structure-based Drug
Discovery;
5: What isn't in this Book;
6: Concluding Remarks;
References;
Chapter 2: Structure Detemination - Crystallography for
Structure-based Drug Design;
1: What is X-ray Crystallography?;
2: What is required to Produce a Crystal Structure?;
3: Crystallisability of Proteins;
4: How Does the X-ray Data Relate to the Electron Density? The
Phase Problem;
5: Electron Density Map Interpretation and Atomic Model of the
Protein;
6: Useful Crystallographic Therminology when Utilising Crystal
Structures;
7: The Structure Determination Process;
8: Recent technological Advances;
9: The Role of Crystal Structures in the Discovery Process;
10: The Optimal SBDD System;
11: The Impact of Structural Genomics;
12: Producing a Biologically Relevant Structure;
13: Phosphorylation;
14: Balancing Solubility with Crystallisability;
15: Engineering Solubility;
16: Specific Crystal Packing Engineering;
17: Engineering Stability;
18: Use of Surrogate Proteins;
References;
Chapter 3: Molecular Modelling;
1: Introduction;
2: Methods;
3: Applications;
4: Conclusion;
References;
Chapter 4: Applications of NMR in Structure-based Drug Design;
1: Introduction;
2: Studying Ligand/Receptor Interactions by NMR;
3: NMR in Structure-based Lead Optimization;
4: Other Applications of NMR in SBDD;
5: Conclusion and Outlook;
References;
Chapter 5:Fragment Screening - An Introduction;
1: Introduction;
2: The Concept of Drug Likeness;
3: The Evolution of Lead-likeness and Fragment Screening;
4: Finding Fragments by Screening;
5: The Design of Fragment Screening Sets;
6: Turning Fragment Hits into Leads;
7:Summary;
References;
Chapter 6: Iterative Structure-based Screening of Virtual Chemical
Libraries and Factor Xa: Finding the Orally Available
Antithrombotic Candadate LY517717;
1: Introduction;
2: Morphology of the Factor Xa Active Site;
3: Structure-based Library Design;
4: Design Strategy for Factor Xa;
5: Introducing Oral Availability;
6: Non-basic S1 Series;
7: Oral Antithrombotic Activity;
8: Conclusion;
References;
Chapter 7: Anti-influenza Drugs from Sialidase Inhibitors;
1: Introduction;
2: Influenza Viruses;
3: Early Attempts to Discover Neuraminidase Inhibitors;
4: Neuraminidase Structure;
5: Structure-based Discovery of Inhibitors;
6: Retrospective Analyses of Inhibitor-binding;
7: Laboratory Studies of Inhibitor Resistant Variants;
8: Clinical Studies of Drug Resistance;
9: Drug Profiles;
Conclusions;
References;
Chapter 8: Isoform Specificity: The Design of Estrogen Receptor-
Selective Compounds;
1: Introduction;
2: Structure-based Design Methodology;
3: The Design of Aryl Diphenolic Azoles as ER? Selective
Agonists;
4: Learning From and Moving Beyond the Genistein Scaffold;
5: Evaluation of ER? Selective Compounds in Biological Assays;
Conclusions;
Acknowledgements;
References
Well written......most illuminating.This is a book that the
practising medicinal chemist should have at the bedside.
*Chemistry & Industry, 26 March 2007 (Christopher Newton)*
....good didactic overview....good artwork reinforcing the
text.....warmly recommend this book to those about to embark on a
structure-based drug design project. There are very few of us who
will invent a drug, but by using the techniques described, you will
shorten your own odds considerably.
*Chemistry World, January 2007, p59 (Richard Lewis)*
|
Ask a Question About this Product More... |
|
